Background: The demonstration of positive signs during neurological examination is a cornerstone of the diagnosis of functional movement disorders, however, the available data supporting the diagnostic value of some of these signs is limited.
Objectives: To determine the diagnostic value (sensitivity and specificity) of the "whack-a-mole" (WAM) and "swivel chair" (SC) tests in patients with functional movement disorders (FMD).
Methods: We enrolled patients with functional and organic movements in the WAM test if they exhibited tremor, dystonia, myoclonus, chorea, or tics. For the SC test, patients with a gait disorder as their primary impairment were recruited. Two blinded movement disorder specialists rated the presence of these signs in edited videos.
Results: Inclusion criteria were met by 42 patients with FMD and 65 patients with organic movement disorders. Both tests demonstrated high specificity (means, 78% and 96%), but their sensitivity was low (means, 52% and 37%). Interobserver agreement for the WAM sign was 0.77 in the FMD group, against 0.28 in patients with organic movement disorders, whereas Movement Disorders Clinical Practice for Review Only for the SC sign was 0.69 in both groups.
Conclusions: The present study indicates that physicians must be cautious in the application and interpretation of these clinical signs in the diagnosis of functional movement disorders, and they should be carefully considered and used as necessary.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10828619 | PMC |
http://dx.doi.org/10.1002/mdc3.13895 | DOI Listing |
Alzheimers Dement
December 2024
School of Medical & Allied Sciences, K.R. Mangalam University, Gurugram, Haryana, India.
Background: Parkinson's disease is an hypokinetic disorder characterized by selective loss of dopaminergic in substantia nigra pars compacta (SNPc) region of mid-brain. Dopaminergic degeneration of neurons is considered to be due to oxidative stress, neuroinflammation, neurons mitochondrial dysfunction and glutamate excitotoxicity etc. Filgrastim has been reported to produce anti-oxidant, anti-inflammatory and neuromodulatory actions in previous studies.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Background: Frontotemporal degeneration (FTD) is an umbrella term encompassing a range of rare neurodegenerative disorders that cause progressive changes to behavior, personality, language, and movement with onset typically before age 60. Currently, several potential FTD therapies are under investigation, underscoring the need for increased diversity in research participation. Two validated scores describe socioeconomic and geographic factors that may impact willingness to participate in research.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
North Bristol NHS Trust, Bristol, United Kingdom.
Background: Poor sleep is associated with neurodegenerative diseases underlying dementia and mild cognitive impairment (MCI), including Alzheimer's disease (AD) and Lewy body disease (LBD). Performing assessments within clinical or laboratory settings may influence validity, however feasibility of home sleep and memory assessments in this population is currently undetermined. This study aimed to identify whether remote home-based sleep and memory research including wearable technology was feasible in older adults with MCI and dementia.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Colorado School of Medicine, Aurora, CO, USA.
Background: Lewy body dementia (LBD) is a common and burdensome neurodegenerative dementia, that remains under-recognized and under-studied. Caregivers play an important role, although research on their needs is lacking. Understanding and addressing their concerns can help improve their well-being, the care they provide for their loved ones, and also participation in research.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Movement Disorders Programs, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Background: Alzheimer's disease (AD) is a significant health concern affecting at least 10% of individuals aged 65 and older, with heightened risk in Black and Hispanic/Latino populations. Despite this prevalence, our analysis of University of California Los Angeles (UCLA) electronic health records (EHR) indicates that only 4% of patients aged 65 or older receive an AD diagnosis, with underdiagnosis more prevalent among Black and Hispanic/Latino patients compared to their white counterparts. To address this issue, we propose implementing a concise dementia screening tool (DST) in real-world clinical settings.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!